Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy

Fig. 1

MCPyV-oncoprotein antibody titers over the course of anti-PD-1 therapy. 15 of 17 (88%) patients with VP-MCC tumors produced antibodies specific for MCPyV small T oncoprotein while no VN-MCC patients produced antibodies. MCPyV-oncoprotein antibody titer was tracked over time in seropositive individuals with available post-treatment serum samples (n = 13). Titers are plotted as percent change from baseline (100%). a) Patients with a complete response experienced a decrease in titer (n = 3). b) Among partial responders (n = 8), titer initially decreased over time in 7 of 8 patients. Two patients subsequently recurred (denoted by *); clinical detection of recurrence was preceded by a rise in titer in both cases

Back to article page